PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.90%
Revenue growth at 50-75% of META's 11.71%. Martin Whitman would worry about competitiveness or product relevance.
8.97%
Gross profit growth at 50-75% of META's 15.61%. Martin Whitman would question if cost structure or brand is lagging.
25.40%
EBIT growth 1.25-1.5x META's 22.02%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
25.40%
Operating income growth 1.25-1.5x META's 22.02%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
22.04%
Net income growth at 50-75% of META's 36.42%. Martin Whitman would question fundamental disadvantages in expenses or demand.
22.88%
EPS growth at 50-75% of META's 37.10%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
23.08%
Diluted EPS growth at 50-75% of META's 35.45%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
-0.88%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.46%
Reduced diluted shares while META is at 0.62%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
21.94%
Similar OCF growth to META's 23.65%. Walter Schloss would assume comparable operations or industry factors.
26.47%
FCF growth under 50% of META's 55.02%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
455.27%
10Y revenue/share CAGR under 50% of META's 1609.29%. Michael Burry would suspect a lasting competitive disadvantage.
150.51%
5Y revenue/share CAGR at 75-90% of META's 175.94%. Bill Ackman would encourage strategies to match competitor’s pace.
109.68%
3Y revenue/share CAGR 1.25-1.5x META's 91.82%. Bruce Berkowitz might see better product or regional expansions than the competitor.
539.62%
10Y OCF/share CAGR under 50% of META's 1168.00%. Michael Burry would worry about a persistent underperformance in cash creation.
210.25%
5Y OCF/share CAGR is similar to META's 213.53%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
120.50%
3Y OCF/share CAGR under 50% of META's 399.99%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
497.37%
Below 50% of META's 2178.64%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
530.41%
5Y net income/share CAGR above 1.5x META's 74.03%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
184.10%
3Y net income/share CAGR above 1.5x META's 68.48%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
255.67%
Below 50% of META's 951.13%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
80.83%
5Y equity/share CAGR at 75-90% of META's 92.65%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
38.69%
3Y equity/share CAGR similar to META's 35.94%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.68%
AR growth well above META's 13.28%. Michael Burry fears inflated revenue or higher default risk in the near future.
-3.63%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
3.67%
Asset growth well under 50% of META's 12.03%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
3.31%
Under 50% of META's 8.20%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-0.17%
We’re deleveraging while META stands at 31.34%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-7.67%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-0.29%
We cut SG&A while META invests at 23.43%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.